KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Other financing activities (2016 - 2025)

Historic Other financing activities for Eli Lilly (LLY) over the last 15 years, with Q3 2025 value amounting to -$30.2 million.

  • Eli Lilly's Other financing activities rose 3615.22% to -$30.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$792.4 million, marking a year-over-year decrease of 6622.61%. This contributed to the annual value of -$490.6 million for FY2024, which is 4644.78% down from last year.
  • As of Q3 2025, Eli Lilly's Other financing activities stood at -$30.2 million, which was up 3615.22% from -$30.4 million recorded in Q2 2025.
  • Eli Lilly's Other financing activities' 5-year high stood at -$500000.0 during Q3 2021, with a 5-year trough of -$686.3 million in Q1 2025.
  • Moreover, its 5-year median value for Other financing activities was -$30.2 million (2025), whereas its average is -$114.6 million.
  • As far as peak fluctuations go, Eli Lilly's Other financing activities skyrocketed by 9855.07% in 2021, and later plummeted by 218333.33% in 2022.
  • Over the past 5 years, Eli Lilly's Other financing activities (Quarter) stood at -$600000.0 in 2021, then tumbled by 2183.33% to -$13.7 million in 2022, then crashed by 130.66% to -$31.6 million in 2023, then crashed by 43.99% to -$45.5 million in 2024, then skyrocketed by 33.63% to -$30.2 million in 2025.
  • Its Other financing activities was -$30.2 million in Q3 2025, compared to -$30.4 million in Q2 2025 and -$686.3 million in Q1 2025.